Geisinger Medical Center

Haymarket Medical Education and myCME, in Partnership With Sleep-Wake Advisor, Announce Launch of the Sleep-Wake Advisor Institute

Retrieved on: 
Wednesday, February 21, 2024
Sports, General Sports, Education, Health, General Health, Other Science, Training, Research, Science, Other Education, Continuing, Geisinger Health System, Advisory board, HME, Geisinger Medical Center, Medical education, News, Quality of life, Hospital, Sleep, Neurology, Perception, Faculty, University, Jools' Annual Hootenanny, Patient, University of California, Knowledge, Medical school, Pharmaceutical industry

“Today is an exciting day in the field of Sleep-Wake medicine,” said Jacqui Brooks, MBBCh, MRCPsych, Vice President, Medical Strategy at Haymarket Medical Education.

Key Points: 
  • “Today is an exciting day in the field of Sleep-Wake medicine,” said Jacqui Brooks, MBBCh, MRCPsych, Vice President, Medical Strategy at Haymarket Medical Education.
  • “The launch of the Sleep-Wake Advisor Institute demonstrates Haymarket’s commitment to sleep medicine and its impact across medicine, and will provide a long-needed, one-of-a-kind resource for sleep-wake clinicians.
  • This year will also see the launch of Sleep-Wake Advisor in Spring 2024 and our Sleep-Wake Advisor Summit in June.”
    “Sleep-Wake Advisor Institute is more than an educational platform.
  • To learn more and become part of the Sleep-Wake Advisor Institute community, CLICK HERE .

Castle Biosciences to Present New Data on its TissueCypher® Barrett’s Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting

Retrieved on: 
Tuesday, October 24, 2023
Research, Genetics, Biotechnology, Other Health, Health, General Health, Other Science, Science, Oncology, Patient, EAC, American College, IND, Identity, New York University Grossman School of Medicine, Medicare, Physician, ACG, Pathology, Cancer, BE, University School, Dysplasia, Geisinger Commonwealth School of Medicine, Risk, American College of Gastroenterology, LGD, HGD, Geisinger Medical Center, Diagnosis, Nursing, Medical imaging, Medicine

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will highlight the impactful risk stratification provided by its TissueCypher® test in patients with Barrett’s esophagus (BE) through two posters at the 2023 American College of Gastroenterology (ACG 2023) Annual Scientific Meeting, taking place Oct. 20-25, in Vancouver, Canada.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will highlight the impactful risk stratification provided by its TissueCypher® test in patients with Barrett’s esophagus (BE) through two posters at the 2023 American College of Gastroenterology (ACG 2023) Annual Scientific Meeting, taking place Oct. 20-25, in Vancouver, Canada.
  • “However, we find that at least half of the patients who progress to EAC come from this “low-risk” population, which tells us that there is a critical need to improve our risk-stratification of these patients.
  • In patients with higher-risk clinicopathologic factors (males with a pathology diagnosis of indefinite for dysplasia (IND) or LGD), TissueCypher identified low-risk patients with predicted progression rates similar to patients with NDBE.
  • Overall, the data show the risk stratification provided by the TissueCypher test can aid physicians and patients in making risk-aligned patient management decisions, such as escalated or de-escalated care, which may lead to improved health outcomes.

TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus

Retrieved on: 
Friday, September 8, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Male, Probability, LGD, Geisinger Medical Center, ISDE, Pathology, Cancer, Medicine, Geisinger Commonwealth School of Medicine, EAC, Congress, BE, HGD, Dysplasia, Physician, Risk, Diagnosis, IND, Pharmaceutical industry, Medical imaging, Patient

Most patients were male (61.8%), under surveillance in a community-based practice (94.9%) and had a diagnosis of non-dysplastic Barrett’s esophagus (NDBE) (95.1%), which is representative of the general BE patient population.

Key Points: 
  • Most patients were male (61.8%), under surveillance in a community-based practice (94.9%) and had a diagnosis of non-dysplastic Barrett’s esophagus (NDBE) (95.1%), which is representative of the general BE patient population.
  • Patients with NDBE are considered to be at low risk for progression based on their clinical risk factors.
  • These data demonstrate that TissueCypher provided impactful risk stratification, independent of clinicopathologic risk factors, to enable risk-aligned management of BE patients.
  • This included objective information to support surveillance-only management for patients with a low risk of progression and escalated surveillance/treatment for patients at high risk of progression.

Geisinger Behavioral Health Center Northeast Celebrates Grand Opening in Moosic

Retrieved on: 
Monday, July 17, 2023
Managed Care, Other Health, Consumer, Mental Health, Other Construction & Property, Infectious Diseases, Commercial Building & Real Estate, Hospitals, Construction & Property, Health Insurance, Other Consumer, Health, Physical Therapy, Acute stress disorder, Acadia Healthcare, Partnership, Depression, Psychosis, Senior, Geisinger Medical Center, Assistant Secretary of Defense for Global Strategic Affairs, Anxiety, Hope, Multimedia, Local government, Hospital, Patient, Outline of health sciences, Adolescence, Strategic Operations, Psychiatry, Bipolar disorder, PTSD, Geisinger

Geisinger Behavioral Health Center Northeast held a ribbon cutting ceremony today to mark the completion of construction and celebrate the joint venture between Geisinger and Acadia Healthcare.

Key Points: 
  • Geisinger Behavioral Health Center Northeast held a ribbon cutting ceremony today to mark the completion of construction and celebrate the joint venture between Geisinger and Acadia Healthcare.
  • View the full release here: https://www.businesswire.com/news/home/20230717678162/en/
    Geisinger Behavioral Health Center Northeast hosts ceremony celebrating opening in Moosic, Pennsylvania.
  • “The support from the local legislators and the community throughout this project has been so encouraging,” said Kelly Ankenbrand, chief executive officer of Geisinger Behavioral Health Center Northeast.
  • A second, 96-bed hospital –Geisinger Behavioral Health Center Danville – is currently in development in Danville and is expected to open in 2025.

Avadel Pharmaceuticals Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-at-Bedtime Oxybate Dosing for Narcolepsy

Retrieved on: 
Tuesday, June 13, 2023
Narcolepsy, Cataplexy, Doctor of Pharmacy, Senior, Gamma-Hydroxybutyric acid, Geisinger Medical Center, DCE, Discrete, Anxiety, Quality of life, Advances in Therapy, Patient, Somnolence, Neurology, Sodium, Developmental Medicine & Child Neurology, Pharmaceutical industry, Medical imaging, Child

The paper, titled “Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment,” was published in Advances in Therapy and can be accessed here .

Key Points: 
  • The paper, titled “Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment,” was published in Advances in Therapy and can be accessed here .
  • “Sodium oxybate has been recognized as a standard of care to treat narcolepsy for more than 20 years, but, until recently, has required two nighttime doses for sufficient therapy.
  • These data underscore the long unmet need for an oxybate treatment that does not require middle-of-the-night dosing.
  • “These data provide insight that the most important driver of oxybate choice is dosing and not sodium content.”

Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022

Retrieved on: 
Thursday, March 2, 2023
Geisinger Medical Center, Annual report, United States Department of Veterans Affairs, SR, FDA, Society of Nuclear Medicine and Molecular Imaging, EST, Heart Failure Society of America, DOD, Society, Research, Commercialization, NAV, Conference, Heart failure, Patient, Form, Bangladesh Technical Education Board, Health, BVA, NIH, Acceleration, Molecular imaging, Duke University School of Medicine, International, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Growth, American College of Cardiology, RCT, Cardiology, Customer experience, Participation, American College, Cryptocurrency, Pharmaceutical industry

Oak Ridge, TN, March 02, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, filed its Annual Report to Shareholders on Form N-CSR on March 1, 2023, disclosing its schedule of portfolio holdings as of December 31, 2022.

Key Points: 
  • In addition, Daxor subsequently announced corporate membership in both the Society of Nuclear Medicine and Molecular Imaging and the Heart Failure Society of America.
  • “In 2022 we successfully completed a working prototype system under DOD contract, our next step is validation and FDA approval for civilian use.
  • Over the course of 2022, over a dozen new research studies on BVA were published in peer-reviewed journals or at society conferences.
  • All callers should dial in approximately 15 minutes prior to the scheduled start time and join the Daxor Corporation conference call using the conference ID: DAXOR.

Geisinger's northeast hospitals certified as Comprehensive Heart Attack Centers

Retrieved on: 
Thursday, September 15, 2022
Geisinger Commonwealth School of Medicine, Certification, Time, Safety, Oxygen, Chest pain, Twitter, Nursing, Emergency medical services, Joint, Muscle tissue, Joint Commission, LinkedIn, Geisinger Medical Center, Heart failure, GMC, Patient, Emergency medicine, Physician, Instagram, Quality of life, Pharmacist, Geisinger, Sarah Cannon Research Institute, GCMC, AHA, EMS, Record, Heart, Pain management, Pharmacy, Hospital, Education, Medical device, Accreditation, Facebook

WlLKES-BARRE, Pa. and SCRANTON, Pa., Sept. 15, 2022 /PRNewswire/ -- Geisinger Wyoming Valley Medical Center (GWV) and Geisinger Community Medical Center (GCMC) recently became the second and third hospitals in the country to earn The Joint Commission/American Heart Association (AHA) Comprehensive Heart Attack Center Certification, joining Geisinger Medical Center (GMC) in Danville in establishing a national precedent for coordination among care teams who treat patients on the heart attack spectrum.

Key Points: 
  • A heart attack occurs when blood flow to the heart is blocked, depriving the heart of oxygen.
  • Much of the damage to heart muscle takes place in a short period of time after a heart attack, so timely care is critical for preserving heart function.
  • "No one expects to have a heart attack, but when it happens, we offer extraordinary care close to home for our patients and members," said Yassir Nawaz, M.D., director of interventional cardiology and co-medical director of the Comprehensive Heart Attack Center Certification program for Geisinger's northeast region.
  • "With three certified medical centers, we're taking a full-team approach to diagnosing and treating chest pain patients in northeastern and central Pennsylvania."

DCG Giving, a Dave Cantin Group Nonprofit, Partners with Children’s Oncology Group to Fight Pediatric Cancer and Support Cutting-Edge Research and Treatment

Retrieved on: 
Wednesday, August 10, 2022
Finance, Consulting, Professional Services, Philanthropy, Other Health, Health, Foundation, Other Philanthropy, Oncology, Other Professional Services, Children's Oncology Group, Hospital, Organic, Children's Hospital Los Angeles, Mergers and acquisitions, St. Jude Children's Research Hospital, Industry, Children's Hospital of Philadelphia, Adolescence, Memorial Sloan Kettering Cancer Center, Research, Organization, DCG, Cincinnati Children's Hospital Medical Center, Patient, Institute for Mergers, Acquisitions and Alliances, Center, Foundation, COG, Johns Hopkins Children's Center, Partnership, Community, Geisinger Medical Center, American Cancer Society, Dana–Farber Cancer Institute, Philadelphia, Seattle Children's, Mobile phone, Birth control, MD, Cancer, Child

Today DCG Giving announced it has entered a partnership with the Children's Oncology Group (COG) the world's largest organization devoted exclusively to childhood and adolescent cancer research and treatment.

Key Points: 
  • Today DCG Giving announced it has entered a partnership with the Children's Oncology Group (COG) the world's largest organization devoted exclusively to childhood and adolescent cancer research and treatment.
  • The goal of DCG Giving is to offer financial and structural support to COGs local child and adolescent cancer programs and assist patients and their families across the country.
  • We are proud to partner with COG, which is trailblazing the advancement for childhood and adolescent cancer research and treatment, said Executive Director Michael Weiner, MD.
  • The organizations mission is to fund lifesaving child and adolescent cancer research and treatment in communities nationwide.

Dr. Ksenia Orlova Joins Top Doctors at Vascular Care Connecticut

Retrieved on: 
Wednesday, April 13, 2022
Hospitals, Health, Surgery, Other Health, Board, University of Pennsylvania Health System, Faculty, Woman, RVT, Diagnosis, FACS, RPVI, Doctor of Philosophy, Patient, Neuroscience, Surgeon, Geisinger Medical Center, Environment, Peripheral artery disease, Method, Aneurysm, University, Safety, Vascular disease, Dentistry, MD

Vascular Care Connecticut , a state-of-the art practice committed to the prevention, diagnosis and treatment of vascular disease, is pleased to announce that Ksenia Orlova, MD, PhD, joined the Darien, Conn. center.

Key Points: 
  • Vascular Care Connecticut , a state-of-the art practice committed to the prevention, diagnosis and treatment of vascular disease, is pleased to announce that Ksenia Orlova, MD, PhD, joined the Darien, Conn. center.
  • Together, these three surgeons bring over 40 years of experience in vascular care to the lower Fairfield County area.
  • Vascular Care Connecticut will allow me to bring my vascular surgical experience to an outpatient setting and utilize minimally invasive techniques to improve patient outcomes, said Dr. Orlova.
  • Vascular Care Connecticut brings together decades of experience to offer unparalleled care in Connecticut and is dedicated to being on the cutting edge of innovation and new technologies for vascular disease and providing patients the care they need in a convenient and uncomplicated environment.

Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and Once-Nightly Dosing Preference Among Patients and Clinicians at World Sleep 2022

Retrieved on: 
Friday, March 11, 2022
Nasdaq, Safety, Drug Quality and Security Act, Securities Act of 1933, Congress, Sodium oxybate, Developmental Medicine & Child Neurology, Sleep medicine, U.S. Securities and Exchange Commission, FDA, Â, Cataplexy, Annual report, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sleep, Quality of life, Neurology, Narcolepsy, Securities Exchange Act of 1934, Medicine, Forward-looking statement, Excessive daytime sleepiness, Geisinger Medical Center, Hypnagogia, GLOBE, Patient, Security (finance), 2021 Essex County Council election, Solution, Sleep paralysis, Knowledge, World Sleep Day, Somnolence, DCE, SEC, Food, Review, EDS, Pharmaceutical industry, Dietary supplement, Risk management, Child, Avadel Pharmaceuticals

New post-hoc data from the completed pivotal Phase 3 REST-ON clinical trial of FT218 and interim data from the ongoing RESTORE open-label extension/switch study of FT218 will also be presented.

Key Points: 
  • New post-hoc data from the completed pivotal Phase 3 REST-ON clinical trial of FT218 and interim data from the ongoing RESTORE open-label extension/switch study of FT218 will also be presented.
  • We know that untreated narcolepsy can have a devastating effect on patients quality of life and ability to function and that additional treatment options would benefit patients and clinicians.
  • All accepted abstracts are available on the World Sleep Congress website and will be published in an upcoming Sleep Medicine journal supplement.
  • At Avadel, we believe in listening to patients to develop solutions that will have a meaningful impact on their symptoms.